Regeneron Pharmaceuticals announced positive Phase III results for cemdisiran, an siRNA therapeutic licensed from Alnylam Pharmaceuticals for generalized myasthenia gravis (MG). The monotherapy showed numerical improvements over combination therapies, reducing complement factor 5 by 74% and improving clinical symptom scores. Regeneron plans to file for FDA approval in early 2026. This progress positions cemdisiran competitively within the growing neuromuscular disease treatment landscape, and the original developer will receive tiered royalties on sales.